What Makes Finch Therapeutics (FNCH) a Worthy Investment?

Core Insights - Arquitos Capital Management reported a net return of 29.6% for Q3 2025, with year-to-date gains reaching 66.8% [1] - The firm focuses on a select group of companies and is willing to hold investments for extended periods [1] Company Highlights - Finch Therapeutics Group, Inc. (OTC:FNCH) is highlighted as a key investment, with a one-month return of -3.59% and a 52-week gain of 16.50% [2] - As of December 10, 2025, Finch Therapeutics' stock closed at $13.98, with a market capitalization of $22.449 million [2] - Finch's share price increased from $11.30 at the beginning of the year to $12.28 at the end of Q3 2025 [3] - The company won a jury trial against Ferring Pharmaceuticals in August 2024, resulting in a $30 million award and potential for enhanced damages due to willful infringement [3] Investment Perspective - Finch Therapeutics is not among the 30 most popular stocks among hedge funds, with the firm suggesting that certain AI stocks may offer better upside potential and lower downside risk [4]